Deferasirox
- Product NDC
- 45963-454
- 11-digit product format
- 459630454
- Labeler code
- 45963
- Product ID
- 45963-454_ff13b6ff-e95c-47ed-b21b-6cac71aff318
- Type
- HUMAN PRESCRIPTION DRUG
- Nonproprietary name
- Deferasirox
- Dosage form
- TABLET, FOR SUSPENSION
- Route
- ORAL
- Labeler
- Actavis Pharma, Inc.
- Application
- ANDA203560
- Marketing category
- ANDA
- Marketing start
- 2019-03-22
- Marketing end
- 0000-00-00
- Substance
- DEFERASIROX
- Active strength
- 125 mg/1
- Pharmacologic classes
- Cytochrome P450 1A2 Inhibitors [MoA], Cytochrome P450 2C8 Inhibitors [MoA], Cytochrome P450 3A4 Inducers [MoA], Iron Chelating Activity [MoA], Iron Chelator [EPC]
- NDC exclude flag
- No
- Listing certified through
- 2024-12-31
- Current FDA listing
- Historical FDA.report record
DailyMed Product Concepts#
DailyMed Package Descriptions#
Package NDC, Product, Description table| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|
| 45963-454-30 | Deferasirox | 30 in 1 BOTTLE | TABLET, FOR SUSPENSION | 30 | | 29 |
DailyMed Dashboard NDC Coverage#
NDC, Dashboard title, SPL version table| NDC | Dashboard title | SPL version | Validation | Dashboard ZIP |
|---|
| 45963-454 | DEFERASIROX TABLET, FOR SUSPENSION [ACTAVIS PHARMA, INC.] | 28 | Legacy NDC, 1 package rows | 20241103_ad73cb1f-41d6-4cde-9abc-fc2cb7e04c95.zip |
DailyMed RxNorm Mappings#
Packages#
Package NDC, 11-digit format, Description table| Package NDC | 11-digit format | Description | Marketing start | Marketing end | Sample | Exclude flag | Status |
|---|
| 45963-454-30 | 45963045430 | 30 TABLET, FOR SUSPENSION in 1 BOTTLE (45963-454-30) | 2019-03-22 | 0000-00-00 | No | No | Current |